

Cardiac Biomarkers Uses and Limitations

Randolph L. Winter, DVM, DACVIM
Assistant Professor, Cardiology
PhD candidate, Biomedical Sciences
Auburn University



Outline

- Introduction
- Testing Strategies
- Clinical Use
 - and limitations
- Biologic Variability
- Summary



INTRODUCTION



What is a Biomarker?

- Measurable substance that indirectly informs about organ health
 - Specific to the organ / tissue
 - Released in proportion to the degree of disease
 - greater damage = greater amounts measured



Organ-specific biomarkers

- Liver biomarker
 - Alanine transferase (ALT)
- Cardiac biomarker
 - B-type natriuretic peptide (BNP)
 - N-terminal pro-B-type natriuretic peptide (NTproBNP)
 - Cardiac troponin I (cTnI)
 - Atrial natriuretic peptide (ANP), and N-terminal pro-Atrial natriuretic peptide (NTproANP)



Liver disease

- How can we know how healthy a patient's liver is?
 - Abdominal palpation
 - Abdominal radiographs
 - Abdominal ultrasonography
 - Blood values such as ALT
 - Liver biopsy
 - Fine-needle aspirate
 - Laparoscopic biopsy
 - Laparotomy to obtain biopsy



ALT

- Present primarily in the hepatocyte cytosol
- ALT released with hepatocyte damage
 - circulates in the systemic blood stream
- ↑↑↑ ALT = ↑↑↑ Liver Damage



Cardiac disease

- How can we assess cardiac health/disease?
 - Cardiac auscultation
 - Thoracic radiographs
 - Echocardiography (cardiac ultrasound)
 - Blood markers such as cTnI or BNP
 - Cardiac Magnetic Resonance Imaging
 - Endomyocardial biopsy



Cardiac biomarkers

- N-terminal pro B-type Natriuretic Peptide (NTproBNP)
- cardiac troponin I (cTnI)
- B-type Natriuretic Peptide (BNP)
- N-terminal pro Atrial Natriuretic Peptide (NTproANP)
- Atrial Natriuretic Peptide (ANP)




Cardiac biomarkers

- *N-terminal pro B-type Natriuretic Peptide (NTproBNP)*
- *cardiac troponin I (cTnI)*
- B-type Natriuretic Peptide (BNP)
- N-terminal pro Atrial Natriuretic Peptide (NTproANP)
- Atrial Natriuretic Peptide (ANP)



Natriuretic peptides (NP)

- pro-BNP and pro-ANP stored as granules
 - mostly atrial tissue
 - lesser degree in ventricular tissue
- Many pro-ANP peptides stored as granules
 - pro-BNP peptides production upregulated in ventricular m.
- C-terminal end is the active hormone




Natriuretic peptides

- Volume Overload = Atrial/Ventricular Stretch
- NPs released to excrete Sodium/Water
- Chronic volume overload = \uparrow BNP/ANP production in myocardium




Natriuretic peptides



Cardiac troponin I (cTnI)

- Troponin subunits are associated with tropomyosin
 - Both cardiac and skeletal muscle
 - troponin subunits C and T
 - the I subunit = only cardiac



Cardiac troponin I

- cTnI mostly bound to the contractile unit
 - Only ~3% cTnI found free in cytosol
- Cardiomyocyte damage = cTnI leaks into the interstitium
 - taken up by cardiac lymphatics
- cTnI then present in systemic circulation
 - lymphatics overwhelmed
- Likely excreted passively by kidneys

Cardiac troponin I

- Healthy hearts do not have high concentrations in circulation
- Level of circulating cTnI in circulation corresponds to the degree of damage
 - cardiomyocyte specific



TESTING STRATEGIES



Screening

- Hypertrophic Cardiomyopathy in cats
- Dilated Cardiomyopathy in dogs
- Myxomatous Mitral Valve Disease in dogs
 - NOT NEEDED
 - **AUSCULTATION PREFERRED**



Screening - HCM

- NTproBNP in 201 cats (99 = normal)¹
 - NTproBNP > 100 pmol/L detected HCM (92.4% sens. and 93.9% spec.)
 - Cats with NTproBNP <100 were unlikely to have HCM
- 92.4% of cats with the disease will test positive (> 100 pmol/L)
- 93.9% of cats without the disease will test negative (<100 pmol/L)

6.1% False Positives

100 pmol/L

7.6% False Negatives




1. Vet Clin Pathol 2011;40:237-244

Screening - DCM

- NTproBNP in 155 Doberman Pinschers¹
 - NTproBNP > 500 pmol/L = likely systolic dysfunction
 - NTproBNP < 500 pmol/L = likely normal LV function

– Screening for Arrhythmia = ECG +/- Holter^{1,2}



1. J Vet Intern Med 2012;26:1330
2. J Vet Cardiol 2017;19:405

Testing strategy

- Not every animal needs cardiac biomarkers measured
- Minimizes false positive
- Clinical decision-making process
- False positives = worry and extra test




Image courtesy of JAVMA 2013; 43:71-82



Testing strategy

- Consider case **A**
 - Very low likelihood of disease (1%) pretest
 - High positive only raises likelihood of disease a small amount
 - 1% → 20%
 - 80% chance of false positive
 - case decision making
- A 1 yo DSH cat, clinically healthy without any history or physical exam signs of cardiovascular disease = low probability of disease
 - Not appropriate to measure NTproBNP as part of the pre-anesthetic bloodwork for this cat's spay




Image courtesy of JAVMA 2013;243:2017
 AUBURN UNIVERSITY
 COLLEGE OF VETERINARY MEDICINE

Testing strategy

- Consider case **B**
 - Start with a 50/50 chance
 - Now test result = very helpful
 - High test result = 95% chance of disease
 - Case decision making
- Measuring NTproBNP in a cat with a murmur
 - A high NTproBNP value = Echocardiography good




Image courtesy of JAVMA 2013;243:2017
 AUBURN UNIVERSITY
 COLLEGE OF VETERINARY MEDICINE

Testing strategy

- Consider case **C**
 - 50/50 chance of disease
 - Low test result = 5% chance of disease
- Adult cat with respiratory distress
 - Ddx: Congestive heart failure vs 1° resp. disease
 - Normal NTproBNP rules out CHF





Image courtesy of JAVMA 2013;243:2017
 AUBURN UNIVERSITY
 COLLEGE OF VETERINARY MEDICINE

CLINICAL USE



NTproBNP in cats

- **SNAP® Feline Cardiopet® proBNP Test**
 - Results within 10 minutes
 - Requires just a few drops of blood
- Normal = $< \sim 100$ pmol/L¹
- Abnormal = $> \sim 270$ pmol/L¹
- *Normal results help rule out CHF*



1. J Vet Cardiol 2014;16:245

PREDICTing heart failure


- MMVD – ACVIM stage B2 dogs¹
 - Thx rads, Echo, NTproBNP, BP
 - NTproBNP > 1500 pmol/L
 - ↑ Risk of CHF within 6 months



1. J Vet Cardiol 2012;14:193

Clinical Case - MMVD


- 7 year old MN CKCS
- Tests:
 - Thx rads
 - Echo
 - BP
 - CBC/Panel/UA
- Follow-up:
 - Thx rads in 8 months
 - BP in 8 months



AUBURN UNIVERSITY
COLLEGE OF
VETERINARY MEDICINE

Clinical Case - MMVD


- Scenario #1



AUBURN UNIVERSITY
COLLEGE OF
VETERINARY MEDICINE

Clinical Case - MMVD


- Scenario #2



AUBURN UNIVERSITY
COLLEGE OF
VETERINARY MEDICINE

Clinical Case – 3° AVB

- 9 yo FS Labrador
- 3° AVB
- Echo normal



Clinical Case - 3° AVB

- Start with atropine response test
 - 0.04 mg/kg IV
 - Perform ECG for 5-10 minutes

No response

cardiac troponin I

Sinus tach ~180 bpm

Evaluate for systemic dz
(ocular, resp, CNS, GI)



Clinical Case - 3° AVB

- cardiac troponin I
 - 0.008 ng/mL
 - No additional tests
 - Likely AV nodal fibrosis
 - 5.3 ng/mL
 - Infectious tests*
 - Likely myocarditis

* Tick-borne bacterial dz
Trypanosoma cruzi
Fungal myocarditis



Cardiac Troponin I

- **Remember!!**

- each lab generates own reference range
- different labs may not be comparable
- Standard- vs. High-sensitivity assays
 - **Standard:** All Healthy dogs and 68% MMVD had undetectable values (below limit of detection)¹
 - **High-sens:** 31% healthy and NO MMVD dogs had undetectable values¹

1. J Vet Cardiol 2017;19:124



BIOLOGIC VARIABILITY




Biologic Variability


- The natural change that occurs in an analyte value, independent of disease severity progression
 - E.g. changes in biomarker values in a healthy dog
 - E.g. changes that occur over some time period in a dog with stable (non-progressive) disease
- Within-subject, between-subject, analytical variation
 - Critical Change Value %




Scientific Line Graph



NTproBNP in Normal Dogs



cTnI in Normal Dogs



BV in MMVD dogs

1

Disease state	Dogs (N)	Samples (N)	CCV-95% (95% CI)
Healthy	10	160	70.8% (62.3–82.1%)
MMVD B1	10	40	73.4% (64.6–85.2%)
MMVD B2	10	40	51.4% (45.2–59.6%)
MMVD C–stable	8	32	53.3% (46.9–61.9%)
All MMVD	28	112	58.2% (51.2–67.5%)

NTproBNP
CCV = 58%

2

	Dogs (n)	Samples (n)	CV, cTnI	CCV*
Healthy	10	111	48%	134%
MMVD B1	10	40	42%	118%
MMVD B2	10	40	33%	91%
MMVD C–stable	8	32	44%	121%
All MMVD	28	112	40%	110%

cTnI
CCV = 110%

AUBURN UNIVERSITY
COLLEGE OF
VETERINARY MEDICINE

1. J Vet Cardiol 2017;19:124
2. Vet Clin Pathol 2017;46:299

How to Apply BV

- Revisit PREDICT study (MMVD)¹
 - NTproBNP > 1500 pmol/L associated with development of CHF at or prior to next visit
- Normal BV for MMVD is <58% for NTproBNP²

1. J Vet Cardiol 2013;14:193
2. J Vet Cardiol 2017;19:124



Patient 1 NTproBNP change of 40%

Previous Visit:
NTproBNP = 1000 pmol/L



Patient 1 CCV = 58%
 NTproBNP change of 40%

Previous Visit:
 NTproBNP = 1000 pmol/L



Today's Visit:
 NTproBNP = 1400 pmol/L



Patient 2 CCV = 58%
 NTproBNP change of 60%

Previous Visit:
 NTproBNP = 800 pmol/L



Patient 2 CCV = 58%
 NTproBNP change of 60%

Previous Visit:
 NTproBNP = 800 pmol/L



Today's Visit:
 NTproBNP = 1280 pmol/L



Summary

- Cardiac biomarkers aren't for every patient
 - Screen for HCM in cats and DCM in Dobies
 - Test to minimize false positives
- Higher values = greater disease
 - Helps determine follow-up tests or referral
- Monitor trends
 - Helps predict prognosis
- Biologic variability important to consider



Questions?